RIO DE JANEIRO, BRAZIL - The Bio-Manguinhos vaccine manufacturing facility at the Oswaldo Cruz Foundation, in northern Rio, is considered the largest in Latin America and is preparing to produce the Covid-19 vaccine developed by Oxford University in the United Kingdom.
The Oxford vaccine is in stage 3, the final stage, which will determine its efficacy on a large number of subjects. The British university this week announced that preliminary trials suggest the vaccine is safe and has induced an immune response in volunteers.
The agreement between Fiocruz and AstraZeneca, the pharmaceutical company that acquired the vaccine from Oxford . . .